Department of Pathology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0436, USA.
Vaccine. 2011 Oct 6;29(43):7444-55. doi: 10.1016/j.vaccine.2011.07.058. Epub 2011 Jul 26.
Recently, we demonstrated that a single-cycle West Nile virus (WNV) named RepliVAX WN could be used to produce a chimeric Japanese encephalitis (JE) vaccine (RepliVAX JE) by replacing the WNV prM/E genes with those of JEV. Here, we tested if replacement of WNV NS1 gene in RepliVAX JE with that of JEV (producing TripliVAX JE) could produce a superior vaccine. TripliVAX JE elicited higher anti-E immunity and displayed better efficacy in mice than RepliVAX JE. Furthermore, TripliVAX JE displayed reduced immune interference caused by pre-existing anti-NS1 immunity. Thus, we propose prM/E/NS1 chimerization as a new strategy for flavivirus vaccine development.
最近，我们证明了一种名为 RepliVAX WN 的单周期西尼罗河病毒 (WNV) 可以通过用 JEV 的 prM/E 基因替换 WNV 的 prM/E 基因来产生嵌合日本脑炎 (JE) 疫苗 (RepliVAX JE)。在这里，我们测试了用 JEV 的 NS1 基因替换 RepliVAX JE 中的 WNV NS1 基因（产生 TripliVAX JE）是否可以产生更好的疫苗。TripliVAX JE 引发了更高的抗-E 免疫反应，并且在小鼠中的功效优于 RepliVAX JE。此外，TripliVAX JE 显示出减少了由预先存在的抗-NS1 免疫引起的免疫干扰。因此，我们提出 prM/E/NS1 嵌合作为黄病毒疫苗开发的新策略。
